论文部分内容阅读
目的：观察卡介苗（ＢＣＧ）膀胱灌注后尿液中ＩＬ－２、ＴＮＦ含量与临床预后的关系。方法：３２例表浅膀胱癌患者术后ＢＣＧ膀胱灌注治疗，采用ＣＴＬＬ－３Ｈ－ＴｄＲ掺入法和夹心法酶联免疫吸附试验分别测定尿液中ＩＬ－２和ＴＮＦ浓度，随访４３．５（２６～６７）个月。结果：３２例患者中有６例复发（１８．７％），复发患者灌注后尿液中ＩＬ－２、ＴＮＦ含量分别为（１４．３４±６．８３）Ｕ／ｍｌ、（７８．６３±３７．４５）ｎｇ／Ｌ，未复发患者含量分别为（２１．４１±９．２３）Ｕ／ｍｌ、（１０６．７６±４９．１３）ｎｇ／Ｌ，复发患者与未复发患者间ＩＬ－２、ＴＮＦ水平均差异显著（Ｐ＜０．０１或０．０５）。结论：尿液中ＩＬ－２、ＴＮＦ含量监测对判断表浅膀胱癌术后ＢＣＧ灌注治疗的预后有重要的参考价值
Objective: To observe the relationship between urinary IL-2 and TNF levels and clinical prognosis of BCG after bladder perfusion. Methods: Thirty-two patients with superficial bladder cancer were treated with intravesical instillation of BCG. The concentrations of IL-2 and TNF in urine were measured by CTLL-3H-TdR incorporation method and sandwich enzyme-linked immunosorbent assay (ELISA) 26 ~ 67) months. Results: Six of 32 patients relapsed (18.7%). The levels of IL-2 and TNF in urine after reperfusion were (14.34 ± 6.83) U / ml and (78.63 ± 37.45) ng / L, and those without recurrence were (21.41 ± 9.23) U / ml and (106.76 ± 49.13) ng / L, respectively , TNF levels were significantly different (P <0.01 or 0.05). Conclusion: The monitoring of urinary IL-2 and TNF levels is of great value in judging the prognosis of postoperative BCG infusion in patients with superficial bladder cancer